

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.com) on Apr 24, 2025

Phospho-TIF1beta (Ser824) Antibody

RRID:AB_2209906

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4127, RRID:AB_2209906)

Antibody Information

URL: http://antibodyregistry.org/AB_2209906

Proper Citation: (Cell Signaling Technology Cat# 4127, RRID:AB_2209906)

Target Antigen: Human TIF1-beta, phospho (Ser824)

Clonality: unknown

Comments: Applications: W

Antibody Name: Phospho-TIF1beta (Ser824) Antibody

Description: This unknown targets Human TIF1-beta, phospho (Ser824)

Target Organism: human

Antibody ID: AB_2209906

Vendor: Cell Signaling Technology

Catalog Number: 4127

Record Creation Time: 20231110T042611+0000

Record Last Update: 20241115T034009+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-TIF1beta (Ser824) Antibody.

No alerts have been found for Phospho-TIF1beta (Ser824) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Huang M, et al. (2023) FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. *Molecular cell*, 83(15), 2810.

Sahgal P, et al. (2023) Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. *iScience*, 26(11), 108169.

Egger T, et al. (2022) A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. *Scientific reports*, 12(1), 5422.

Ka NL, et al. (2021) IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. *Cell reports*, 37(12), 110138.